{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:58:47Z","timestamp":1782943127766,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd012862","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000}}],"reference-count":141,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012862.pub2","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T14:07:39Z","timestamp":1617113259000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interventions for atypical haemolytic uraemic syndrome"],"prefix":"10.1002","volume":"2021","author":[{"given":"Dan","family":"Pugh","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine; Royal Infirmary of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin D","family":"O'Sullivan","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine; Royal Infirmary of Edinburgh; Edinburgh UK"},{"name":"Centre for Inflammation Research; Royal Infirmary of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona AI","family":"Duthie","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine; Royal Infirmary of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Masson","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine; Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Renal Department; Newcastle University\/Freeman Hospital; Newcastle Upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0001|cit1","first-page":"751A","article-title":"Eculizumab safety and efficacy in adult patients with aHUS, with or without baseline dialysis [abstract no: SA-PO507]","volume":"25","author":"Fakhouri","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0002|cit2","first-page":"751A","article-title":"Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-year update [abstract no: SA-PO508]","volume":"25","author":"Fakhouri","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0004|cit4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2179.2179","article-title":"Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult patients (pts) with atypical hemolytic uremic syndrome (aHUS) [abstract no: 2179]","volume":"122","author":"Fakhouri","year":"2013","journal-title":"Blood"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0005|cit5","first-page":"752A","article-title":"Safety and efficacy of eculizumab in adult aHUS patients, with or without a history of renal transplant [abstract no: SA-PO511]","volume":"25","author":"Loirat","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0006|cit6","first-page":"537","article-title":"Inhibition of complement-mediated thrombotic microangiopathy with eculizumab improves hematological and renal outcomes in adult patients with atypical hemolytic uremic syndrome [abstract no: S1371]","volume":"99","author":"Minetti","year":"2014","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1186\/cc13295","article-title":"Eculizumab treatment of atypical haemolytic uraemic syndrome: Results from the largest prospective clinical trial to date [abstract]","volume":"18","author":"Weekers","year":"2014","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0008|cit8","first-page":"S2","article-title":"Eculizumab for the treatment of atypical haemolytic uraemic syndrome: Results from the largest prospective clinical trial to date in adults [abstract]","volume":"70","author":"Weekers","year":"2015","journal-title":"Acta Clinica Belgica"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0009|cit9","first-page":"191A","article-title":"Safety of eculizumab in pediatric patients with atypical hemolytic uremic syndrome [abstract no: TH-PO460]","volume":"26","author":"Ariceta","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0010|cit10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2191.2191","article-title":"Eculizumab (ECU) inhibits Thrombotic Microangiopathy (TMA) and improves renal function in pediatric patients (Pts) with atypical Hemolytic Uremic Syndrome (aHUS) [abstract]","volume":"122","author":"Greenbaum","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0011|cit11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4986.4986","article-title":"Eculizumab inhibits Thrombotic Microangiopathy and improves renal function in pediatric patients with Atypical Hemolytic Uremic Syndrome: 1-year update [abstract no: 4986]","volume":"124","author":"Greenbaum","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0013|cit13","first-page":"1670","article-title":"Evaluation of eculizumab treatment of paediatric patients with atypical haemolytic uraemic syndrome: a prospective clinical trial [abstract]","volume":"29","author":"Van De Kar","year":"2014","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0014|cit14","first-page":"761A","article-title":"Safety and efficacy of eculizumab in pediatric patients with aHUS, with or without baseline dialysis [abstract no: SA-PO546]","volume":"25","author":"Vande Walle","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0015|cit15","first-page":"191A","article-title":"Safety of eculizumab in pediatric patients with atypical hemolytic uremic syndrome [abstract no: TH-PO460]","volume":"26","author":"Ariceta","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012862.pub2-BIB0016|cit16","first-page":"651","article-title":"Eculizumab is effective in patients resistant to plasma exchange\/infusion with atypical hemolytic uremic syndrome (AHUS) [abstract no: P-WE-419]","volume":"9","author":"Bedrosian","year":"2011","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0017|cit17","first-page":"318","article-title":"Long-term improvements in outcomes with eculizumab in aHUS patients with progressing TMA [abstract]","volume":"68","author":"Davin","year":"2013","journal-title":"Acta Clinica Belgica"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0018|cit18","first-page":"199A","article-title":"Eculizumab (ECU) is effective in patients (pts) with atypical hemolytic uremic syndrome (aHUS) regardless of underlying genetic mutations or complement factor H (CFH) auto-antibodies [abstract no: TH-PO442]","volume":"23","author":"Goodship","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD012862.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.molimm.2011.06.368","article-title":"Interim analysis of phase II efficacy and safety data for eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion [abstract]","volume":"48","author":"Goodship","year":"2011","journal-title":"Molecular Immunology"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0020|cit20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2084.2084","article-title":"Eculizumab (ECU) in atypical hemolytic uremic syndrome (AHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data [abstract no: 2084]","volume":"120","author":"Greenbaum","year":"2012","journal-title":"Blood"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0021|cit21","first-page":"197A","article-title":"Continued improvements in renal function with sustained eculizumab (ECU) in patients (Pts) with atypical Hemolytic Uremic Syndrome (aHUS) resistant to plasma exchange\/infusion (PE\/PI) [abstract no: TH-PO366]","volume":"22","author":"Greenbaum","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0022|cit22","first-page":"201","article-title":"Safety & efficacy of eculizamab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial [abstract]","volume":"22","author":"Legendre","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD012862.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0024|cit24","first-page":"1660","article-title":"A phase II study of eculizumab in adolescent\/adult patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/infusion: interim efficacy and safety analysis [abstract no: PS2-FRI-272]","volume":"26","author":"Licht","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012862.pub2-BIB0025|cit25","first-page":"651","article-title":"A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) receiving chronic plasma exchange\/infusion: interim analysis [abstract no: P-WE-418]","volume":"9","author":"Licht","year":"2011","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0026|cit26","first-page":"197A","article-title":"Ph II study of eculizumab (ECU) in patients (pts) with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange\/iinfusion (PE\/PI) [abstract no: TH-PO366]","volume":"22","author":"Licht","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0027|cit27","first-page":"1660","article-title":"Eculizumab in adolescents\/adult patients with atypical hemolytic uremic syndrome resistant to plasma exchange\/infusion: a phase II efficacy and safety study [abstract no: PS2-FRI-273]","volume":"26","author":"Loirat","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0028|cit28","first-page":"402A","article-title":"Safety & efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial [abstract no: F-PO1274]","volume":"21","author":"Muus","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0029|cit29","first-page":"191A","article-title":"Safety of eculizumab in pediatric patients with atypical hemolytic uremic syndrome [abstract no: TH-PO460]","volume":"26","author":"Ariceta","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0030|cit30","first-page":"91","article-title":"Progressing thrombotic microangiopathy in atypical haemolytic uraemic syndrome patients: long term improvements in outcomes with eculizumab [abstract no: P212]","volume":"98","author":"Douglas","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"10.1002\/14651858.CD012862.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V126.23.2252.2252","article-title":"Eculizumab prevents thrombotic microangiopathy: long-term follow-up study of patients with atypical hemolytic uremic syndrome [abstract no: 2252]","volume":"126","author":"Greenbaum","year":"2016","journal-title":"Blood"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0032|cit32","first-page":"88","article-title":"Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients (pts) with progressing TMA: continued improvements at 2-year follow-up [abstract no: SA-OR101]","volume":"23","author":"Legendre","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney International"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0034|cit34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2186.2186","article-title":"Time to hematologic and renal improvements in atypical hemolytic uremic syndrome patients with long disease duration and chronic kidney disease (CKD) treated with eculizumab [abstract]","volume":"122","author":"Licht","year":"2013","journal-title":"Blood"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0035|cit35","first-page":"89A","article-title":"Eculizumab (ECU) is effective in atypical hemolytic uremic syndrome (aHUS) patients (pts) with a long disease duration and CKD: 2-year data [abstract no: SA-OR103]","volume":"23","author":"Licht","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0036|cit36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.985.985","article-title":"Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results [abstract no: 985]","volume":"120","author":"Licht","year":"2012","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0037|cit37","first-page":"i310","article-title":"Long-term improvements in outcomes with eculizumab in patients with atypical haemolytic uraemic syndrome and progressing TMA [abstract no: MP036]","volume":"28","author":"Sheerin","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment [Erratum in: Kidney Int. 2020 Dec;98(6):1621; PMID: 33276869]","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012862.pub2-BIB0039|cit39","first-page":"793","article-title":"Preemptive plasma therapy and eculizumab (ECU) rescue for atypical hemolytic uremic syndrome (AHUS) relapse following kidney transplantation (KTX) [abstract no: C76]","volume":"18","author":"Aigner","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"i592","DOI":"10.1093\/ndt\/gfy104.SP730","article-title":"Preemptive plasma therapy and eculizumab rescue for atypical hemolytic uremic syndrome relapse following kidney transplantation [abstract no: SP730]","volume":"33","author":"Aigner","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejim.2019.11.007","article-title":"Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients","volume":"73","author":"Aigner","year":"2020","journal-title":"European Journal of Internal Medicine"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood.V120.21.2085.2085","article-title":"Eculizumab is an effective treatment for atypical hemolytic uremic syndrome in patients with or without identified genetic complement mutations or complement factor H auto-antibodies [abstract no: 2085]","volume":"120","author":"Al-Akash","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012862.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.transproceed.2019.01.157","article-title":"Renal transplantation in patients with atypical hemolytic uremic syndrome: a single center experience","volume":"51","author":"Alpay","year":"2019","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0044|cit44","article-title":"Eculizumab for the treatment of atypical hemolytic uremic syndrome in pediatric patients, a tertiary care hospital experience [abstract]","volume":"34","author":"Alsakran","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012862.pub2-BIB0045|cit45","first-page":"682","article-title":"Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome-single center experience [abstract no: A232]","volume":"19","author":"Bhalla","year":"2019","journal-title":"American Journal of Transplantation"},{"issue":"22","key":"10.1002\/14651858.CD012862.pub2-BIB0046|cit46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2255.2255","article-title":"Eculizumab therapy of adult TA-TMA: A high response rate is associated with a high infection-related mortality [abstract no: 2255]","volume":"128","author":"Bohl","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000492865","article-title":"Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury","volume":"48","author":"Cao","year":"2018","journal-title":"American Journal of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0048|cit48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2789.2789","article-title":"Eculizumab Is an effective treatment for atypical hemolytic uremic syndrome in pediatric and adult patients with or without identified genetic complement mutations or complement factor H autoantibodies [abstract no: 2789]","volume":"124","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0049|cit49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2184.2184","article-title":"Biomarkers of complement and endothelial activation, inflammation, thrombosis and renal injury in patients (pts) with aHUS treated with eculizumab (ECU) [abstract no: 2184]","volume":"122","author":"Cofiell","year":"2013","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012862.pub2-BIB0050|cit50","first-page":"iii339","article-title":"Eculizumab reduces terminal complement (TC) and complement alternative pathway (CAP) activation, inflammation, endothelial damage, thrombosis and renal injury in atypical hemolytic uremic syndrome (aHUS) patients [abstract no: MP035]","volume":"29","author":"Cofiell","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"21","key":"10.1002\/14651858.CD012862.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0052|cit52","first-page":"750A","article-title":"Eculizumab reduces terminal complement, complement alternative pathway activation, inflammation, endothelial damage, thrombosis and renal injury markers in patients with atypical hemolytic uremic syndrome [abstract no: SA-PO506]","volume":"25","author":"Cofiell","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012862.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"iii58","DOI":"10.1093\/ndt\/gfx120","article-title":"Eculizumab in secondary atypical hemolytic uremic syndrome [abstract]","volume":"32","author":"Escribano","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012862.pub2-BIB0054|cit54","first-page":"286","article-title":"Thirty-six consecutive kidney transplants in recipients with atypical hemolytic uremic syndrome: a single-centre experience [abstract]","volume":"18","author":"Favi","year":"2018","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ki.2015.253","article-title":"The emerging role of complement inhibitors in transplantation","volume":"88","author":"Fremeaux-Bacchi","year":"2015","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0056|cit56","first-page":"1871","article-title":"Long-term outcome after hemolytic uremic syndrome in childhood [abstract no: PO-332]","volume":"31","author":"Frykman","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"23","key":"10.1002\/14651858.CD012862.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"A88","DOI":"10.1136\/ejhpharm-2016-000875.199","article-title":"Effectiveness and safety of eculizumab in atypical haemolytic uraemic syndrome and thrombotic microangiopathy [abstract]","volume":"23","author":"Gomez-Alvarez","year":"2016","journal-title":"European Journal of Hospital Pharmacy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012862.pub2-BIB0060|cit60","first-page":"660","article-title":"Eculizumab (ECU) therapy for atypical hemolytic uremic syndrome (AHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study [abstract no: P-WE-444]","volume":"9","author":"Rodig","year":"2011","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3747\/pdi.2019.00094","article-title":"Acute candida albicans peritonitis in a patient with atypical hemolytic uremic syndrome treated with eculizumab","volume":"39","author":"Han","year":"2019","journal-title":"Peritoneal Dialysis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0062|cit62","article-title":"Relationship between pharmacokinetics and antidrug antibody status of ABP 959, a biosimilar candidate to eculizumab: results from a pharmacokinetic similarity study [abstract no: 128621]","volume":"134","author":"Hanes","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","article-title":"Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Ito","year":"2019","journal-title":"Clinical & Experimental Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12882-020-01847-0","article-title":"Ten-year outcome of eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience","volume":"21","author":"Kant","year":"2020","journal-title":"BMC Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","article-title":"Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Kato","year":"2019","journal-title":"Clinical & Experimental Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0067|cit67","first-page":"1886","article-title":"Multicenter cohort of atypical hemolytic uremic syndrome (aHUS) in Indian children [abstract no: PO-378]","volume":"31","author":"Khandelwal","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jca.21711","article-title":"Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety","volume":"34","author":"Khandelwal","year":"2019","journal-title":"Journal of Clinical Apheresis"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0069|cit69","first-page":"752A","article-title":"Time to end-stage renal disease in patients with atypical hemolytic uremic syndrome receiving supportive care and eculizumab [abstract no: SA-PO509]","volume":"25","author":"Khursigara","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/jpc.14390","article-title":"Eculizumab in paediatric atypical haemolytic uraemic syndrome: lessons learned from a single-centre experience in the United Arab Emirates","volume":"55","author":"Kumar","year":"2019","journal-title":"Journal of Paediatrics & Child Health"},{"issue":"19","key":"10.1002\/14651858.CD012862.pub2-BIB0071|cit71","first-page":"1745","article-title":"Therapeutic complement inhibition - from experimental to clinical medicine","volume":"135","author":"Lappegard","year":"2015","journal-title":"Tidsskrift for Den Norske Laegeforening"},{"issue":"22","key":"10.1002\/14651858.CD012862.pub2-BIB0072|cit72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2421.2421","article-title":"Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab [abstract no: 2421]","volume":"114","author":"Legault","year":"2009","journal-title":"Blood"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0073|cit73","first-page":"S325","article-title":"Outcome after eculizumab therapy to prevent recurrence of atypical hemolytic uremic syndrome: experience in twelve renal transplant recipients [abstract no: 550.9]","volume":"100","author":"Levi","year":"2016","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0074|cit74","first-page":"1788","article-title":"Efficacy of treatment with eculizumab in children with aHUS [abstract no: P-338]","volume":"32","author":"Mazo","year":"2017","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0075|cit75","first-page":"435","article-title":"Ongoing eculizumab (ECU) prevents thrombotic microangiopathy (TMA) in patients (pts) with atypical hemolytic uremic syndrome (aHUS): final long-term observational study data [abstract no: FR-PO136]","volume":"28","author":"Menne","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012862.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ckj\/sfy035","article-title":"Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study","volume":"12","author":"Menne","year":"2019","journal-title":"Clinical Kidney Journal"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012862.pub2-BIB0078|cit78","first-page":"458A","article-title":"Eculizumab prevents thrombotic microangiopathy in atypical hemolytic uremic syndrome patients: long-term follow-up [abstract no: FR-PO446]","volume":"26","author":"Menne","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012862.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"iii572","DOI":"10.1093\/ndt\/gfx170.MP393","article-title":"Long-term safety and effectiveness of eculizumab for patients with atypical haemolytic uraemic syndrome: Outcomes from a prospective observational clinical trial [abstract]","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD012862.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","article-title":"Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study","volume":"35","author":"Monet-Didailler","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/MJT.0b013e31829b59dc","article-title":"Atypical hemolytic-uremic syndrome: a clinical review","volume":"23","author":"Nayer","year":"2016","journal-title":"American Journal of Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012862.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","article-title":"Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases","volume":"25","author":"Nester","year":"2013","journal-title":"Current Opinion in Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD012862.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.molimm.2006.10.005","article-title":"A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation","volume":"44","author":"Nilsson","year":"2007","journal-title":"Molecular Immunology"},{"issue":"11","key":"10.1002\/14651858.CD012862.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0085|cit85","first-page":"1757","article-title":"Outcomes from an observational clinical trial evaluating the long-term safety and effectiveness of eculizumab use in paediatric patients with atypical haemolytic uraemic syndrome (aHUS) [abstract no: FP-S30-2]","volume":"31","author":"Pape","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0086|cit86","first-page":"1662","article-title":"Improved outcomes for paediatric patients with atypical haemolytic uraemic syndrome (AHUS) receiving long-term eculizumab treatment during on-treatment periods compared with off-treatment periods [Abstract no: O-46]","volume":"32","author":"Pape","year":"2017","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.patbio.2015.03.001","article-title":"Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome","volume":"63","author":"Picard","year":"2015","journal-title":"Pathologie Biologie"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.12659\/AOT.909781","article-title":"Effect of immunosuppressive therapy on the occurrence of atypical hemolytic uremic syndrome in renal transplant recipients","volume":"23","author":"Raina","year":"2018","journal-title":"Annals of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"KI Reports"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0090|cit90","first-page":"1663","article-title":"Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study [abstract no: PS2-FRI-288]","volume":"26","author":"Simonetti","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012862.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2010","journal-title":"British Journal of Haematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1136\/ejhpharm-2013-000436.243","article-title":"Efficacy of eculizumab in adult patients with atypical hemolytic uremic syndrome resistant to plasma treatment [abstract]","volume":"21","author":"Ubago Perez","year":"2014","journal-title":"European Journal of Hospital Pharmacy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"i97","DOI":"10.1093\/ndt\/gfy104.FP199","article-title":"Efficacy and safety of the eculizumab on haemolytic uremic syndrome [abstract]","volume":"33","author":"Uriol","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012862.pub2-BIB0096|cit96","first-page":"479","article-title":"Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: Efficacy and safety outcomes of a retrospective study [abstract]","volume":"97","author":"Vilalta","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Seminars in Thrombosis & Hemostasis"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.imbio.2016.06.038","article-title":"Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome [abstract]","volume":"31","author":"Volokhina","year":"2016","journal-title":"Immunobiology"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0099|cit99","first-page":"1757","article-title":"Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical HUS [abstract no: FP-S30-1]","volume":"31","author":"Volokhina","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012862.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"iii85","DOI":"10.1093\/ndt\/gfx130.TO018","article-title":"Timing of eculizumab initiation and the need for dialysis in patients with atypical haemolytic uraemic syndrome undergoing kidney transplantation [abstract]","volume":"32","author":"Walle","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.molimm.2013.05.072","article-title":"Phase 1 clinical trial of novel complement C5 inhibitor coversin [abstract]","volume":"56","author":"Weston-Davies","year":"2013","journal-title":"Molecular Immunology"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0103|cit103","first-page":"1883","article-title":"Safety and effectiveness of restricted eculizumab regimen in atypical HUS [abstract no: PO-371]","volume":"31","author":"Wijnsma","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012862.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","author":"Wong","year":"2015","journal-title":"Translational Research: The Journal Of Laboratory & Clinical Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0105|cit105","first-page":"112","article-title":"The long-acting complement inhibitor ravulizumab in children with atypical hemolytic uremic syndrome (interim analysis) [abstract]","volume":"40","author":"Wuhl","year":"2020","journal-title":"Nieren und Hochdruckkrankheiten"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0106|cit106","unstructured":"An international study at different study sites providing a drug called cemdisiran (ALN-CC5) to patients with atypical hemolytic uremic syndrome by a subcutaneous injection www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-001082-24 2017"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0107|cit107","unstructured":"A study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of study drug OMS721 in adults with thrombotic microangiopathies www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2014-001032-11"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0108|cit108","unstructured":"The safety and efficacy of eculizumab in Japanese patients with atypical hemolytic uremic syndrome (aHUS) www.clinicaltrials.gov\/show\/NCT01757431"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0109|cit109","unstructured":"Study of ravulizumab in children and adolescents with atypical hemolytic uremic syndrome (aHUS) www.clinicaltrials.gov\/show\/NCT03131219"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0110|cit110","unstructured":"Leifke E Safety and efficacy study of OMS721 in patients with atypical hemolytic uremic syndrome (aHUS) www.clinicaltrials.gov\/show\/NCT03205995"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0111|cit111","unstructured":"Nangaku M Observational study of atypical hemolytic uremic syndrome in Japan upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000017280"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"687-96","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD012862.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00467-015-3278-0","article-title":"Liver transplantation for aHUS: still needed in the eculizumab era?","volume":"31","author":"Coppo","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"10095","key":"10.1002\/14651858.CD012862.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome [Erratum in: Lancet. 2017 Aug 12;390(10095):648; PMID: 28438379]","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"7650","key":"10.1002\/14651858.CD012862.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD012862.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0120|cit120","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"62-73","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12185-010-0748-9","article-title":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial","volume":"93","author":"Kanakura","year":"2011","journal-title":"International Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD012862.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"34-45","DOI":"10.5582\/irdr.2014.01001","article-title":"Current treatment of atypical hemolytic uremic syndrome","volume":"3","author":"Kaplan","year":"2014","journal-title":"Intractable & Rare Diseases Research"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012862.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MPH.0b013e318095057a","article-title":"Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F)","volume":"29","author":"Lai","year":"2007","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0002-9343(99)00286-7","article-title":"Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"107","author":"Coe","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012862.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003595.pub2","article-title":"Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura","author":"Michael","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012862.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD012862.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012862.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"11","key":"10.1002\/14651858.CD012862.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2005.00783.x","article-title":"Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation","volume":"5","author":"Remuzzi","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD012862.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0136|cit136","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0137|cit137","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD012862.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"10.1002\/14651858.CD012862.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD012862.pub2-BIB0140|cit140","first-page":"1670","article-title":"Evaluation of eculizumab treatment of paediatric patients with atypical haemolytic uraemic syndrome: a prospective clinical trial [abstract]","volume":"29","author":"Van De Kar","year":"2014","journal-title":"Pediatric Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD012862.pub2-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012862","article-title":"Interventions for atypical haemolytic uraemic syndrome","author":"Pugh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T16:47:35Z","timestamp":1631465255000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012862.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":141,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012862.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}